Integra LifeSciences Inc. (IART) - Cash per Single Share

Stable demand for Integra LifeSciences (IART) consumables is based on the conservatism of surgeons who choose proven neuro-instruments. The deep integration of these brands within clinics minimizes the risks of switching suppliers, even during plant optimization. The cash per share metric demonstrates liquidity, with the current level sitting around 4.03. This confirms management's ability to implement innovations and restore industry trust following production disruptions.
Comprehensive metric breakdowns and analytics for Integra LifeSciences Inc. (IART)

Integra LifeSciences, a manufacturer of medical implants, is subject to rigorous FDA inspections and product recall risks, necessitating a substantial liquidity buffer. By analyzing the cash per share metric, an investor can determine the ratio of net cash to the number of shares, allowing for an assessment of the company's financial resilience in the face of regulatory shocks and the efficiency of its capital management.